GILD
Gilead Sciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$151.00
−0.15%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
16.7x
EV/EBITDA
330.5x
Market Cap
$187.23B
MomentumView details →
1D Return
−0.15%
YTD Return
+23.11%
RSI (14)
68.0
ValuationView details →
P/E (Fwd)
16.7x
EV/EBITDA
330.5x
Market Cap
$187.23B
RSI (14)
68.0
MomentumView details →
1D Return
−0.15%
YTD Return
+23.11%
SummaryUpdated Jun 1, 2026
Gilead Sciences, Inc. (NASDAQ:GILD) is a leading biopharmaceutical company founded in 1987 and headquartered in Foster City, California. The company went public in 1992 and has established itself as a major player in the pharmaceutical industry, particularly known for its groundbreaking treatments in HIV/AIDS, hepatitis, and oncology. Gilead has built its reputation through innovative drug discovery and development, with a focus on addressing unmet medical needs in serious diseases. The company operates globally, serving patients in the United States, Europe, and international markets through its comprehensive portfolio of specialized medicines.
Similar companies
Latest newsMore news →
Zambia received its first US-funded shipment of lenacapavir, an HIV prevention drug developed by Gilead Sciences, at the University Teaching Hospital in Lusaka on Wednesday.2d agoThe FDA approved Priovant Therapeutics' Lisraya for dermatomyositis, Gilead Sciences' Bixlenvo for HIV, and an expanded cardiovascular indication for Eli Lilly's Mounjaro.7d agoThe U.S. FDA approved Gilead Sciences' Bixlenvo, a once-daily single tablet regimen for virologically suppressed adults with HIV, including those on complex regimens.8d ago